Human epidermal growth factor receptor 2 (HER2)-positive breast cancers are effectively managed by a combination of anthracyclines (e.g., DOX) and trastuzumab (Trz), a humanized anti-HER2/ErbB2 drug [235]. The gene discussed is ERBB2; the disease is breast carcinoma.